BCG Revaccination Study in Diabetic and Non-Diabetic Adults - Trial NCT06246851
Access comprehensive clinical trial information for NCT06246851 through Pure Global AI's free database. This phase not specified trial is sponsored by University of Oxford and is currently Recruiting. The study focuses on Tuberculosis. Target enrollment is 36 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
University of Oxford
Timeline & Enrollment
N/A
Feb 01, 2024
Nov 01, 2027
Primary Outcome
Intradermal vs. aerosol BCG in non-type 2 diabetics,Intradermal (in type 2 diabetics) vs intradermal (in non-type 2 diabetics)
Summary
The purpose of this study is to:
 
 1. explore whether investigators can make BCG more effective by giving it in a different
 way. For this, aerosol inhaled BCG will be compared against the conventional BCG
 injection.
 
 2. explore if there are differences in response to re-vaccination in healthy volunteers
 with and without Type 2 Diabetes.
 
 It will involve 36 previously BCG-vaccinated participants. Bronchoscopies will be performed
 14 days post-challenge to measure BCG recovered from bronchial samples. Blood tests will be
 taken to look at potential immunological markers of immunity.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06246851
Non-Device Trial